British manufacturing boosted by further GSK investments

By Dan Stanton

- Last updated on GMT

UK's Patent Box encouraged recent investments, GSK says
UK's Patent Box encouraged recent investments, GSK says

Related tags: Investment, Uk, Gsk

GSK has committed itself to the UK for the long-term with an investment of £200m ($328m) across two of its manufacturing sites.

GSK were at the forefront of pushing the UK government to cut corporate tax on income generated by homegrown products and in April this year the Patent Box​ was introduced, setting the tax level at 10%.

As part of GSK’s ongoing commitment to the UK, the firm announced this morning it was pumping an additional £200m into its Ware, Hertfordshire and Worthing, Sussex sites.

GSK spokesman Kalpesh Joshi told in-Pharmatechnologist.com the firm is committed to the UK for the long-term, and this latest announcement comes on the back of a number of recent investments.

“We have a fantastic workforce here in the UK which is important and naturally, the implementation of the patent box has made the UK a more attractive place to invest,”​ he said.

Ware is both an R&D and manufacturing site but the investment will add capability to produce GSK’s respiratory device, the Relvar Ellipta inhaler, which received European Marketing Approval last month.

Furthermore the location is the preferred site for a centre of manufacturing innovation the firm intends to build dedicated to turning new science and technologies into practical manufacturing applications.

Worthing produces both active ingredients and formulated drugs and will benefit from a new bulk sterile building and filling line for the antibiotic Augmentin.

The company initially pledged £370m​ in a new facility in Ulverston, Cumbria which is currently being built, and has spent a further £130m on expanding plants in Montrose and Irvine, both in Scotland. Such investment has created almost 1,000 jobs for the UK, the firm said.

Late last month a further £25m was invested into the API facility​ in Montrose in order to support the delivery of its new pipeline.

Related news

Show more

Related products

show more

A Culture of Innovation as a Differentiation

A Culture of Innovation as a Differentiation

Softigel by Procaps | 06-Dec-2021 | Product Presentation

We create safe, effective and differentiated pharmaceutical solutions and this has been our goal since day 1. The main driver of our growth is innovation...

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Related suppliers

Follow us

Products

View more

Webinars